Compare Stocks: ALLO, MAZE, KLRA, and STOK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.18 -5.6%	$1.62	$1.04 ▼ $4.46	$407.68M	0.56	7.05 million shs	9.76 million shs
KLRA Kailera Therapeutics	$12.86 -4.1%	$13.29	$9.76 ▼ $28.23	$1.67B	N/A	1.25 million shs	868,388 shs
MAZE Maze Therapeutics	$31.48 -1.4%	$27.49	$21.95 ▼ $53.65	$1.75B	2.16	797,524 shs	327,051 shs
STOK Stoke Therapeutics	$26.29 -0.2%	$27.43	$20.32 ▼ $40.22	$1.70B	1.26	1.20 million shs	1.86 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-5.60%	-23.38%	-37.23%	-3.28%
KLRA Kailera Therapeutics	0.00%	+0.08%	+16.59%	-24.09%	+1,285,999,900.00%
MAZE Maze Therapeutics	0.00%	+1.52%	+18.12%	+16.94%	+0.70%
STOK Stoke Therapeutics	0.00%	+4.99%	+1.08%	-8.91%	-16.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.18 -5.6%	$1.62	$1.04 ▼ $4.46	$407.68M	0.56	7.05 million shs	9.76 million shs
KLRA Kailera Therapeutics	$12.86 -4.1%	$13.29	$9.76 ▼ $28.23	$1.67B	N/A	1.25 million shs	868,388 shs
MAZE Maze Therapeutics	$31.48 -1.4%	$27.49	$21.95 ▼ $53.65	$1.75B	2.16	797,524 shs	327,051 shs
STOK Stoke Therapeutics	$26.29 -0.2%	$27.43	$20.32 ▼ $40.22	$1.70B	1.26	1.20 million shs	1.86 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-5.60%	-23.38%	-37.23%	-3.28%
KLRA Kailera Therapeutics	0.00%	+0.08%	+16.59%	-24.09%	+1,285,999,900.00%
MAZE Maze Therapeutics	0.00%	+1.52%	+18.12%	+16.94%	+0.70%
STOK Stoke Therapeutics	0.00%	+4.99%	+1.08%	-8.91%	-16.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.79	Moderate Buy	$8.30	603.39% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	232.43% Upside
MAZE Maze Therapeutics	3.07	Buy	$64.45	104.75% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.17	68.00% Upside

Current Analyst Ratings Breakdown

Latest ALLO, MAZE, KLRA, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$43.00
10/21/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/21/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Sell (D)
10/19/2026	MAZE Maze Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$75.00
10/19/2026	MAZE Maze Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$75.00
10/6/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/6/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (D-)
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00
9/23/2026	ALLO Allogene Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$50.00

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	20,383.91	N/A	N/A	$1.30 per share	0.91
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	$167.50M	10.44	N/A	N/A	$7.38 per share	4.27
STOK Stoke Therapeutics	$184.42M	9.20	N/A	N/A	$6.17 per share	4.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-862.07%	-66.76%	-58.10%	N/A

Latest ALLO, MAZE, KLRA, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ALLO Allogene Therapeutics	-$0.1466	N/A	N/A	N/A	$0.00 million	N/A
10/29/2026	Q3 2026	STOK Stoke Therapeutics	-$0.9291	-$1.08	-$0.1509	-$1.08	$8.21 million	$11.26 million
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
KLRA Kailera Therapeutics	N/A	11.11	11.11
MAZE Maze Therapeutics	0.09	18.31	18.31
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
KLRA Kailera Therapeutics	N/A
MAZE Maze Therapeutics	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
KLRA Kailera Therapeutics	N/A
MAZE Maze Therapeutics	5.30%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	152	345.49 million	299.89 million	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	Optionable
MAZE Maze Therapeutics	141	55.55 million	52.61 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

ALLO, MAZE, KLRA, and STOK Headlines

Recent News About These Companies

Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...

October 31 at 9:22 AM | finance.yahoo.com

Stoke Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

October 30 at 8:20 AM | marketscreener.comM

Stoke Therapeutics announces third quarter 2026 financial results and provides business updates

October 30 at 8:20 AM | msn.com

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript

October 30 at 3:00 AM | seekingalpha.com

Earnings Flash (STOK) Stoke Therapeutics Posts Q3 Loss $1.08, vs. FactSet Est of $0.93 Loss

October 29 at 10:19 PM | marketscreener.comM

Stoke Therapeutics Q3 Earnings Call Highlights

October 29 at 10:13 PM | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

October 29 at 8:06 PM | zacks.com

Stoke Therapeutics (NASDAQ:STOK) Announces Quarterly Earnings Results

October 29 at 5:55 PM | marketbeat.com

Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q3 Revenue $11.3M, vs. FactSet Est of $8.2M

October 29 at 5:18 PM | marketscreener.comM

Stoke Therapeutics (STOK) Projected to Post Quarterly Earnings on Thursday

October 24, 2026 | americanbankingnews.com

Stoke Therapeutics (STOK) Projected to Announce Earnings on Thursday

October 24, 2026 | marketbeat.com

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

October 22, 2026 | finance.yahoo.com

STOK - Stoke Therapeutics, Inc.

October 20, 2026 | seekingalpha.com

Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.9% - Time to Buy?

October 20, 2026 | marketbeat.com

Stoke Therapeutics: The Market Misread A Key FDA Win

October 19, 2026 | seekingalpha.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - October 16, 2026

October 18, 2026 | biospace.comB

Stoke Therapeutics grants 245,920 options on Stoke Therapeutics stock

October 18, 2026 | ad-hoc-news.deA

Assenagon Asset Management S.A. Acquires 52,394 Shares of Stoke Therapeutics, Inc. $STOK

October 18, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25

October 18, 2026 | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 16, 2026 | businesswire.com

Stoke Therapeutics, Inc. Presents Data Supporting Disease-Modifying Potential Of STK-002 In Autosomal Dominant Optic Atrophy At The American Academy Of Ophthalmology 2026 ...

October 13, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALLO, MAZE, KLRA, and STOK Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.18 -0.07 (-5.60%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$1.20 +0.02 (+1.36%)

As of 10/30/2026 07:58 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Kailera Therapeutics NASDAQ:KLRA

$12.86 -0.55 (-4.10%)

As of 10/30/2026 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Maze Therapeutics NASDAQ:MAZE

$31.48 -0.45 (-1.41%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$31.40 -0.09 (-0.27%)

As of 10/30/2026 07:30 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Stoke Therapeutics NASDAQ:STOK

$26.29 -0.06 (-0.23%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$26.30 +0.01 (+0.02%)

As of 10/30/2026 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLO, MAZE, KLRA, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLO, MAZE, KLRA, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLO, MAZE, KLRA, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALLO, MAZE, KLRA, and STOK Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Kailera Therapeutics NASDAQ:KLRA

Maze Therapeutics NASDAQ:MAZE

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLO, MAZE, KLRA, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLO, MAZE, KLRA, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLO, MAZE, KLRA, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALLO, MAZE, KLRA, and STOK Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Kailera Therapeutics NASDAQ:KLRA

Maze Therapeutics NASDAQ:MAZE

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools